Cardiology

An analysis of more than 8000 patients with HIV and hypertension suggests these patients may not be receiving the most efficacious antihypertensive agents and this could be placing these patients at increased risk of cardiovascular disease events or death.

The once-daily tablet is indicated for adult patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia

An analysis of the DAPA-HF trial indicates the impact of dapagliflozin were consistent across both men and women receiving the SGLT2 inhibitor.

Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.

Dr. Nisha Parikh provides additional insight into the AHA's latest scientific statement, which highlights the need for greater attention and emphasis on the impact of adverse pregnancy outcomes on cardiovascular risk in women.

A study from the ESC Acute CardioVascular Care 2021 Online Congress is providing clinicians with further insight into the effects of psychosocial stress on the cardiovascular health of men.

High blood pressure at a younger age could forecast cardiovascular problems in adulthood.

The PCSK9 inhibitor was linked to 27% mean reduction in LDL-C over 12 weeks.

An interview with a phase 2 investigator on the the novel drug's potential in a field it wasn't originally designed to treat.

Announced in a statement by the FDA on April 1, the PCKS9 inhibitor alirocumab is now indicated as an add-on therapy for the treatment of homozygous familial hypercholesterolemia.

New phase 2 data from a 24-week assessment suggest the first-in-class drug could benefit exercise and pulmonary-vascular outcomes.

Results of the phase 2 PULSAR trial indicate sotatercept could be an effective adjunct to background medical therapy for reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

A study from Canada is calling for additional attention to paid to the screening, diagnosis, and treatment of primary aldosteronism in adult patients.

The supplemental approval for Tyvaso comes on the basis of clinical evidence showing benefit for pulmonary and cardiovascular outcomes in adult patients.

A subgroup analysis from DAPA-HF show the SGLT2 inhibitor provided efficacy regardless of HFrEF patient gender.

An analysis of the YOUNG-MI registry suggests patients aged 50 or younger who suffer a heart attack were at nearly twice the risk of mortality if they had a diagnosis of a systemic inflammatory disease, such as rheumatoid arthritis and lupus, when compared to their counterparts without an inflammatory disease.

Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.

Dr. Gregory Weiss, a critical care cardiologist, offers perspective on a study examining disparities in the diagnosis and treatment of women who experience acute myocardial infarction.

Investigators determined that acid-base disturbances like lactate clearance influenced C diff infection after cardiac surgery.

An analysis of the CHAMP-HF registry indicates KCCQ-OS was more sensitive at tracking changes in disease state among heart failure patients, indicating the importance of including patient-reported outcome measures in heart failure management.

Researchers compare the NYHA class identifier with KCCQ-QS.

The American Heart Association is highlighting the effect of adverse pregnancy outcomes on risk of cardiovascular disease later in life among women. Check out this interview with the chair of the writing committee for more perspective on the statement.

New research suggests use of PET/CT imaging can help identify neurological changes that can signal increased risk of Takotsubo cardiomyopathy, which is commonly referred to as broken heart syndrome.

The FDA announced approval for the Harmony Transcatheter Pulmonary Valve device for treatment of patients with native or surgically-repaired right ventricular outflow tract was awarded to Medtronic Inc.

Data from a single center, retrospective cohort study conducted in Israel suggests undergoing TAVR could lead to improvements in kidney function among patients with aortic stenosis.